Literature DB >> 28443471

Suppressing the molecular signaling pathways involved in inflammation and cancer in breast cancer cell lines MDA-MB-231 and MCF-7 by miR-590.

Azar Sheikholeslami1, Mohammad Nabiuni2, Ehsan Arefian3.   

Abstract

Breast cancer is the most frequent cancer among women worldwide. Tumor immunology suggests relationships between the immune system, chronic inflammation, and cancer. The immune system may either prevent or promote carcinogenesis. Here, we evaluated molecular signaling pathways common in inflammation and cancer and detected the microRNAs which play pivotal roles in mediating these pathways. Using bioinformatics assays, signaling pathways common in inflammation and cancer, and microRNAs mediating these pathways were identified. MiR-590 was selected and cloned into the pLenti-III-eGFP vector and transfected into the breast cancer cell lines. The expression level of microRNA and the candidate genes was evaluated by real-time quantitative reverse transcription polymerase chain reaction, and the apoptosis level in transfected cells was measured by Annexin V-7AAD assay. The cell migration was tested by real-time quantitative reverse transcription polymerase chain reaction for MMP2/MMP9. The expression levels of miR-590 and the selected genes (i.e. JAK2, PI3K, MAPK1, and CREB) were measured 72 h after transfection. While miR-590 showed an over-expression, the genes were significantly down-regulated. A significant increase was observed in apoptosis level in both cell lines and MMP2/MMP9 was significantly decreased in MDA-MB-231 cells. MiR-590 was selected as a microRNA which triggers and down-regulates critical genes of signaling pathways similar in cancer and inflammation. Following the miR-590 treatment, JAK2, PI3K, MAPK1, and CREB were down-regulated and the apoptosis level was increased in breast cancer cell lines. Apparently, some microRNAs can be good candidates for novel treatments of cancer. Although miR-590 showed good results in this study, further studies are required to investigate the role of miR-590 in breast cancer therapy.

Entities:  

Keywords:  Breast cancer; hsa-miR-590; inflammation; microRNAs

Mesh:

Substances:

Year:  2017        PMID: 28443471     DOI: 10.1177/1010428317697570

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  6 in total

1.  Dietary walnut altered gene expressions related to tumor growth, survival, and metastasis in breast cancer patients: a pilot clinical trial.

Authors:  W Elaine Hardman; Donald A Primerano; Mary T Legenza; James Morgan; Jun Fan; James Denvir
Journal:  Nutr Res       Date:  2019-03-10       Impact factor: 3.315

2.  The anticarcinogen activity of β-arbutin on MCF-7 cells: Stimulation of apoptosis through estrogen receptor-α signal pathway, inflammation and genotoxicity.

Authors:  Ömer Hazman; Ayşenur Sarıova; Mehmet Fatih Bozkurt; İbrahim Hakkı Ciğerci
Journal:  Mol Cell Biochem       Date:  2020-09-22       Impact factor: 3.396

Review 3.  Breast cancer in sub-Saharan Africa: The current state and uncertain future.

Authors:  Claudia A Anyigba; Gordon A Awandare; Lily Paemka
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-29

4.  HHV-6A/6B Infection of NK Cells Modulates the Expression of miRNAs and Transcription Factors Potentially Associated to Impaired NK Activity.

Authors:  Roberta Rizzo; Irene Soffritti; Maria D'Accolti; Daria Bortolotti; Dario Di Luca; Elisabetta Caselli
Journal:  Front Microbiol       Date:  2017-10-31       Impact factor: 5.640

Review 5.  Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer.

Authors:  Stefano Sechi; Anna Frappaolo; Angela Karimpour-Ghahnavieh; Roberto Piergentili; Maria Grazia Giansanti
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

6.  Hierarchical structural component modeling of microRNA-mRNA integration analysis.

Authors:  Yongkang Kim; Sungyoung Lee; Sungkyoung Choi; Jin-Young Jang; Taesung Park
Journal:  BMC Bioinformatics       Date:  2018-05-08       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.